Health Care & Life Sciences » Biotechnology | Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
111,985.00
135,789.00
220,030.00
267,265.00
50,688.00
361,918
Depreciation, Depletion & Amortization
1,277.00
3,690.00
5,247.00
5,611.00
8,092.00
12,245
Other Funds
226.00
-
-
-
519,099.00
68,905
Funds from Operations
76,964.00
106,403.00
181,450.00
230,053.00
134,535.00
280,768
Changes in Working Capital
12,269.00
22,136.00
31,985.00
15,767.00
97,461.00
107,892
Net Operating Cash Flow
64,695.00
128,539.00
149,465.00
245,820.00
231,996.00
388,660
Capital Expenditures
3,775.00
26,825.00
4,833.00
6,866.00
21,215.00
Purchase/Sale of Investments
7,897.00
132,205.00
13,243.00
83,327.00
282,600.00
Net Investing Cash Flow
11,672.00
159,030.00
8,410.00
90,193.00
178,815.00
Issuance/Reduction of Debt, Net
89.00
94.00
17,003.00
7,603.00
200.00
Net Financing Cash Flow
145,671.00
104,155.00
147,808.00
378,129.00
888,082.00
Net Change in Cash
69,304.00
183,414.00
6,753.00
42,116.00
477,271.00
Free Cash Flow
67,065.00
153,983.00
152,866.00
251,161.00
243,996.00
Other Sources
-
-
-
-
125,000.00
Change in Capital Stock
145,986.00
104,249.00
130,805.00
385,732.00
369,183.00

About Sarepta Therapeutics

View Profile
Address
215 First Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.sareptatherapeutics.com
Updated 07/08/2019
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.